MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Tumor Debulking

Surgically removing as much of the tumor as possible. Also known as cytoreductive surgery in the pelvic/abdominal area.

HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma

Oncotarget 2017 February 7 [Epub ahead of print] [Link] Pellegrini L, Xue J1 Larson D, Pastorino S, Jube S, Forest KH, Saad-Jube ZS, Napolitano A, Pagano I, Negi VS, Bianchi ME, Morris P, Pass HI, Gaudino G, Carbone M, Yang H Abstract Human malignant mesothelioma (MM) is an aggressive cancer linked to asbestos and erionite […]

Comments Off on HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma

Peritoneal Deciduoid Mesothelioma

International Journal of Surgical Pathology 2017 January [Epub ahead of print] [Link] Dominiak N, Graybill W, Gunning W, Richardson MS, Spruill LS Abstract This report highlights a diagnostically challenging case of diffuse deciduoid mesothelioma occurring in the peritoneum of a 25-year-old woman, 8 months postpartum. Optimally debulked tumor consisted of sheets of polygonal cells arranged […]

Comments Off on Peritoneal Deciduoid Mesothelioma

Mentored experience of establishing a national peritoneal malignancy programme – Experience of first 50 operative cases

European Journal of Surgical Oncology 2016 November [Epub ahead of print] [Link] Chang KH, Kazanowski M, Staunton O, Cahill RA, Moran BJ, Shields C, Mulsow J Abstract BACKGROUND: Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) are considered standard of care for pseudomyxoma peritonei (PMP) and selected patients with colorectal peritoneal metastases (CPM) or peritoneal […]

Comments Off on Mentored experience of establishing a national peritoneal malignancy programme – Experience of first 50 operative cases

Malignant pleural mesothelioma with lacrimal gland metastasis

Acta Ophthalmologica 2016 December 9 [Epub 2016 July 16] [Link] Hanafi H, Verdijk RM, Paridaens D Abstract PURPOSE: To describe a rare clinical case of biopsy-proven metastatic mesothelioma of the lacrimal gland which responded well to chemo and radiation therapy. METHODS: Interventional case report. RESULTS: A 55-year-old woman with an untreated malignant biopsy-proven pleural mesothelioma […]

Comments Off on Malignant pleural mesothelioma with lacrimal gland metastasis

Chest wall resection for mesothelioma recurrence after surgery

Asian Cardiovascular & Thoracic Annals 2016 November [Epub 2016 October 9] [Link] Bertoglio P, Fanucchi O, Ricciardi S, Chella A, Lucchi M, Mussi A Abstract Malignant pleural mesothelioma is an aggressive and usually fatal disease, and its optimal management is still under debate. Surgery for recurrent malignant mesothelioma has been reported rarely in highly selected […]

Comments Off on Chest wall resection for mesothelioma recurrence after surgery

Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group

Lung Cancer 2016 November [Epub 2016 September 5] [Link] Armato SG, Blyth KG, Keating JJ, Katz S, Tsim S, Coolen J, Gudmundsson E, Opitz I, Nowak AK Abstract Imaging plays an important role in the detection, diagnosis, staging, response assessment, and surveillance of malignant pleural mesothelioma. The etiology, biology, and growth pattern of mesothelioma present […]

Comments Off on Imaging in pleural mesothelioma: A review of the 13th International Conference of the International Mesothelioma Interest Group

A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207

Journal of Thoracic Oncology 2016 November [Epub 2016 July 20] [Link] Wheatley-Price P, Chu Q, Bonomi M, Seely J, Gupta A, Goss G, Hilton J, Feld R, Lee CW, Goffin JR, Maksymiuk A, Murray N, Hagerman L, Bradbury PA Abstract There is no approved second-line systemic therapy option for malignant pleural mesothelioma (MPM), but targeting […]

Comments Off on A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207

Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab

Journal of Thoracic Oncology 2016 November [Epub 2016 August 17] [Link] Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, Orlandi A, Ferroni P, Schlom J, Guadagni F, Hassan R Abstract NTRODUCTION: The functional aspects of programmed death 1 (PD-1) and PD ligand 1 (PD-L1) immune checkpoints in malignant mesothelioma have not […]

Comments Off on Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab

Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET

Molecular Cancer Therapeutics 2016 October 19 [Epub ahead of print] [Link] Terwisscha van Scheltinga AG, Ogasawara A, Pacheco G, Vanderbilt A, Tinianow J, Gupta N2, Li D, Firestein R, Marik J, Scales SJ, Williams SP Abstract Antibody-drug conjugates (ADCs) use monoclonal antibodies (mAb) as vehicles to deliver potent cytotoxic drugs selectively to tumor cells expressing […]

Comments Off on Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET

Systemically administered RNAi molecule sensitizes malignant pleural mesothelioma cells to pemetrexed therapy

Molecular Pharmaceutics 2016 October 14 [Epub ahead of print] [Link] Abu Lila AS, Fukushima M, Huang CL, Wada H, Ishida T Abstract Pemetrexed (PMX) is a key drug for the treatment of malignant pleural mesothelioma (MPM). However, its therapeutic efficacy is cruelly restricted in many clinical settings by the over-expression of thymidylate synthase (TS) gene. […]

Comments Off on Systemically administered RNAi molecule sensitizes malignant pleural mesothelioma cells to pemetrexed therapy